UPDATE - Bionano Genomics Hosts Day 1 of 2022 Symposium with Six Presentations Highlighting the Superior Performance of OGM in Variant Detection for Constitutional Genetic Diseases
January 10 2022 - 7:48PM
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping
(OGM) solutions on the Saphyr® system and provider of NxClinical™,
the leading software solutions for visualization, interpretation
and reporting of genomic data, hosted today the first of four days
of 2022 Symposium, the Company’s premiere event showcasing OGM
research applications across key clinical areas of constitutional
genetic disease, hematologic malignancies, solid tumors and OGM
combined with next-generation sequencing (NGS).
Six presentations from leading researchers across North
America and Europe kicked off Symposium. Today’s event
featured six informative speakers from leading researchers across
North America and Europe. These presentations covered a wide range
of constitutional genetic diseases in pre- and postnatal genetics
and offered insight into potential applications in infertility and
reproductive medicine. The presenters supported OGM as an effective
alternative to traditional workflows such as karyotype, fluorescent
in situ hybridization (FISH), chromosomal microarray (CMA) and
Southern blot. Research presentations have demonstrated greater
sensitivity, better resolution and faster results from OGM
workflows compared to traditional methods.
Performance of OGM evaluated in pre- and postnatal
samples. Both Dr. Iqbal from University of Rochester
Medical Center and Dr. Shirley Heggarty compared the performance of
OGM in the evaluation of pre- and postnatal samples with known
chromosomal aberrations. These studies found a high concordance of
OGM results compared to traditional methods. In addition, OGM was
able to identify both unbalanced structural chromosome
abnormalities and balanced structural variants (SVs), like
translocations and inversions, that chromosomal microarray (CMA)
could not.
Capabilities of OGM to measure repeat expansions were
evaluated. Dr. Alexander Hoischen specifically explored
the capabilities of OGM to map repeat expansions, which can be
particularly challenging types of SVs, in subjects with Canvas
syndrome and myotonic dystrophy types 1 and 2. The OGM workflow was
able to immediately call very large insertions with greater
precision than the standard cytogenetic techniques and with 100%
concordance. OGM was shown to allow researchers the ability to see
more of the genome, while being less time-consuming and
labor-intensive than other molecular methodologies like Southern
blotting, as Dr. Nikhil Sahajpal discovered. Results from his
validation study were 100% concordant with traditional methods and
demonstrated a streamlined laboratory workflow for different sample
types.
The role of OGM as a discovery tool in reproductive
disorders including infertility. In addition to pre- and
postnatal applications, two speakers, Dr. Laila El-Khattabi and
Chaim Jalas, shared how the OGM workflow plays a significant role
in their research in infertility and reproductive disorders. In her
study, Dr. El-Khattabi used OGM to characterize apparently balanced
SVs related to male infertility and identify new genes involved in
reproductive disorders. Chaim Jalas shared how OGM used in
preimplantation genetic diagnosis can identify structural
rearrangements, including balanced translocations and inversions,
in embryos prior to transfer, which they indicated could improve
pregnancy and delivery rates in an IVF setting.
Among 37 posters appearing in the virtual exhibition
hall the top poster per application area selected to compete for
best poster of Symposium. In addition to the oral
presentations, 37 posters were received and selected for
presentation in the virtual exhibition hall. These posters, in the
virtual exhibition hall, were voted on by attendees of Symposium
and a winner was named in each of four key application areas based
on total number of votes. Below are the four poster winners:
- Constitutional cytogenomics: Dr. Catherine A. Brownstein,
Boston Children’s Hospital
- Hematologic malignancies: Dr. Jonathan L. Lühmann, Hannover
Medical School
- Solid tumors: Dr. Miriam Bornhorst, Children’s National
Hospital
- OGM + NGS: Dr. Nikhil Sahajpal, Augusta University
“Sincere congratulations to our poster winners and thanks to all
poster authors for sharing emerging research on OGM from their
laboratories,” remarked Alka Chaubey, PhD, FACMG, chief medical
officer of Bionano. “This event is made possible with the
enthusiastic participation of the OGM community.”
“We are thrilled at this strong kick-off to the 2022 Symposium
and we are excited about the data shared today by experts from
around the world that continues to demonstrate the utility of OGM
workflows in variant detection for constitutional genetic
diseases,” commented Erik Holmlin, PhD, president and chief
executive officer of Bionano. “Congratulations to the poster
winners. We are impressed by all the discoveries our customers are
making with OGM towards the goal of elevating human health.”
Don’t miss Symposium, register now! Symposium
registration is open to all and there is no charge for attending
this event. Register today at
https://www.labroots.com/ms/virtual-event/bngo2022
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen business, the Company also
provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. Through its BioDiscovery business,
the Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. For more information, visit
www.bionanogenomics.com, www.lineagen.com or
www.biodiscovery.com.
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) convey uncertainty of future events or outcomes and
are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the ability for
additional data to support the strength of OGM workflows as
compared to traditional workflows, the ability and utility of OGM
to analyze genomes and reveal answers in genetic disease and cancer
research in less time-consuming and less-labor intensive manners
than traditional workflows, and the potential for OGM to become
part of the standard of care. Each of these forward-looking
statements involves risks and uncertainties. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with: the
impact of the COVID-19 pandemic on our business and the global
economy; general market conditions; changes in the competitive
landscape, including the introduction of competitive technologies
or improvements in existing technologies; failure of future study
results to support those demonstrated during the presentations
referenced in this press release; changes in our strategic and
commercial plans; our ability to obtain sufficient financing to
fund our strategic plans and commercialization efforts; the ability
of medical and research institutions to obtain funding to support
adoption or continued use of OGM or our technologies; and the risks
and uncertainties associated with our business and financial
condition in general, including the risks and uncertainties
described in our filings with the Securities and Exchange
Commission, including, without limitation, our Annual Report on
Form 10-K for the year ended December 31, 2020 and in other filings
subsequently made by us with the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made and are
based on management’s assumptions and estimates as of such date. We
do not undertake any obligation to publicly update any
forward-looking statements, whether as a result of the receipt of
new information, the occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics,
Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1 (858)
366-3243amy@juniper-point.com
Media Relations:Michael SullivanSeismic+1 (503)
799-7520michael@teamseismic.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Sep 2023 to Sep 2024